3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
16
Neoplasms
4
Neoplasm Metastasis
4
Prostatic Neoplasms
3
Multiple Myeloma
3
Giant Cell Tumor of Bone
3
Carcinoma, Renal Cell
3
Smoldering Multiple Myeloma
2
Recurrence
2
Osteoporosis
2
Melanoma
2
Kidney Neoplasms
2
Bone Cysts, Aneurysmal
2
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Thyroid Cancer Metastatic
1
Parathyroid Neoplasms
1
Osteoporotic Fractures
1
Osteopetrosis, mild autosomal recessive form
1
Osteopetrosis, Autosomal Recessive 7
1
Osteoblastoma
1
Neoplastic Cells, Circulating
1
Musculoskeletal Pain
1
Mastocytosis, Systemic
1
Lung Neoplasms
1
Inflammatory Breast Neoplasms
1
Hyperparathyroidism, Primary
1
Granuloma, Giant Cell
1
Giant Cell Tumors
1
Interventions
Paclitaxel
11
Carboplatin
8
Radiotherapy
6
Cyclophosphamide
6
Trastuzumab
5
Chemotherapy, Adjuvant
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
Epirubicin
3
Doxorubicin
3
Cryosurgery
3
Cisplatin
3
pertuzumab
2
Surgical Procedures, Operative
2
Radiotherapy, Conformal
2
Radiation
2
Letrozole
2
Lapatinib
2
Cryotherapy
2
Brachytherapy
2
talimogene laherparepvec
1
sargramostim
1
ferric carboxymaltose
1
atezolizumab
1
aldesleukin
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Zoledronic Acid
1
Vorinostat
1
VPS Coriolus versicolor extract
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Ductal, Breast
×
Denosumab
×
Clear all
NCT02682693
2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2
Completed
780 enrolled